Cargando…
Cepharanthine Ameliorates Pulmonary Fibrosis by Inhibiting the NF-κB/NLRP3 Pathway, Fibroblast-to-Myofibroblast Transition and Inflammation
Pulmonary fibrosis (PF) is one of the sequelae of Corona Virus Disease 2019 (COVID-19), and currently, lung transplantation is the only viable treatment option. Hence, other effective treatments are urgently required. We investigated the therapeutic effects of an approved botanical drug, cepharanthi...
Autores principales: | Chen, Guangrui, Li, Jian, Liu, Huimeng, Zhou, Huiyu, Liu, Mingqiu, Liang, Di, Meng, Zhiyun, Gan, Hui, Wu, Zhuona, Zhu, Xiaoxia, Han, Peng, Liu, Taoyun, Gu, Ruolan, Liu, Shuchen, Dou, Guifang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864377/ https://www.ncbi.nlm.nih.gov/pubmed/36677811 http://dx.doi.org/10.3390/molecules28020753 |
Ejemplares similares
-
Bioavailability Enhancement of Cepharanthine via Pulmonary Administration in Rats and Its Therapeutic Potential for Pulmonary Fibrosis Associated with COVID-19 Infection
por: Li, Jian, et al.
Publicado: (2022) -
Cepharanthine Dry Powder Inhaler for the Treatment of Acute Lung Injury
por: Liang, Di, et al.
Publicado: (2023) -
In vitro and in vivo safety studies indicate that R15, a synthetic polyarginine peptide, could safely reverse the effects of unfractionated heparin
por: Li, Tong, et al.
Publicado: (2021) -
Combined Silver Sulfadiazine Nanosuspension with Thermosensitive Hydrogel: An Effective Antibacterial Treatment for Wound Healing in an Animal Model
por: Liu, Xiaoya, et al.
Publicado: (2023) -
Evaluation of the metabolism of PEP06, an endostatin-RGDRGD 30-amino-acid polypeptide and a promising novel drug for targeting tumor cells
por: Niu, Liyun, et al.
Publicado: (2022)